Esophageal Carcinoma

Complex MONDO:0019086 Pathograph 13 Show in embeddings browser esophageal cancer carcinoma

Esophageal carcinoma is a heterogeneous epithelial malignancy of the esophagus comprising two biologically and epidemiologically distinct histologic subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC dominates globally and is concentrated in East Asia, parts of Africa, and along the "esophageal cancer belt", and is driven largely by tobacco, alcohol, and other carcinogenic environmental exposures acting on stratified squamous mucosa. EAC predominates in Western populations, arises almost exclusively from Barrett metaplasia in the setting of chronic gastroesophageal reflux and obesity, and resembles chromosomally unstable gastric adenocarcinoma molecularly. Both subtypes typically present late with dysphagia and weight loss, carry a poor prognosis, and are managed with multimodality regimens combining surgery, chemoradiotherapy, and PD-1-directed immunotherapy.

Ask OpenScientist

Ask a research question about Esophageal Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
1
Histopath.
4
Phenotypes
13
Pathograph
5
Genes
5
Medical Actions
2
Subtypes
4
Datasets
2
Trials
1
Deep Research
◆

Subtypes

2
Esophageal Squamous Cell Carcinoma
Squamous-cell histology arising from the stratified squamous mucosa of the esophagus. Dominant subtype worldwide; strongly linked to tobacco, alcohol, and other environmental carcinogens; molecularly characterized by frequent TP53 loss-of-function and recurrent alterations in cell-cycle, squamous differentiation, NOTCH, and PI3K/AKT pathways.
Show evidence (1 reference)
PMID:28052061 SUPPORT Human Clinical
"Beyond known histopathological and epidemiologic distinctions, molecular features differentiated oesophageal squamous cell carcinomas from oesophageal adenocarcinomas."
TCGA shows ESCC and EAC are molecularly distinct, supporting the histologic-subtype dichotomy.
Esophageal Adenocarcinoma
Gland-forming malignancy arising in the distal esophagus from Barrett metaplastic mucosa after chronic gastroesophageal reflux. Western-population predominant; characterized by chromosomal instability, near-universal TP53 alteration, and a targetable ERBB2-amplified subset.
Show evidence (1 reference)
PMID:34503107 SUPPORT Human Clinical
"Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
Confirms EAC almost universally arises from Barrett metaplasia driven by chronic GERD.
⚙

Pathophysiology

4
ESCC Carcinogen-Driven Squamous Transformation
In esophageal squamous cell carcinoma, chronic exposure of stratified squamous epithelium to tobacco-derived carcinogens and acetaldehyde from alcohol metabolism produces DNA damage and mutational burden that selects for TP53 loss-of-function and recurrent alterations in cell-cycle, squamous differentiation, and NOTCH signaling.
epithelial cell of esophagus CL:0002252 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves epithelial cell of esophagus (CL:0002252). CL:0002252 is a cell type from the Cell Ontology.
DNA repair GO:0006281 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased DNA repair (GO:0006281). GO:0006281 is a biological process from the Gene Ontology. ↓ DECREASED
esophagus UBERON:0001043 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in esophagus (UBERON:0001043). UBERON:0001043 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Adaptive Immune Resistance Expanding ESCC tumors acquire PD-L1-linked checkpoint programs that enable immune escape.
Dysphagia Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
Weight Loss Tumor burden and impaired oral intake contribute to weight loss.
Show evidence (2 references)
PMID:20224883 SUPPORT Human Clinical
"Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
Identifies tobacco and alcohol as principal upstream drivers of ESCC carcinogenesis.
PMID:28052061 SUPPORT Human Clinical
"Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
Supports distinct ESCC genomic landscape with squamous-lineage transcription-factor amplifications.
Barrett Metaplasia to EAC Sequence
In esophageal adenocarcinoma, chronic gastroesophageal reflux drives columnar (Barrett) metaplasia of the distal esophageal mucosa, which progresses through dysplasia to invasive adenocarcinoma. The transition is accompanied by progressive TP53 inactivation and accumulating chromosomal instability with recurrent copy-number changes including ERBB2 amplification.
epithelial cell of esophagus CL:0002252 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves epithelial cell of esophagus (CL:0002252). CL:0002252 is a cell type from the Cell Ontology.
epithelial cell differentiation GO:0030855 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal epithelial cell differentiation (GO:0030855). GO:0030855 is a biological process from the Gene Ontology. ⚠ ABNORMAL
esophagus UBERON:0001043 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in esophagus (UBERON:0001043). UBERON:0001043 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Barrett Esophagus (Precursor Lesion) Columnar (Barrett) metaplasia of the distal esophageal mucosa is the obligate histologic precursor of EAC.
Chromosomal Instability and Mutator Phenotype Progressive TP53 inactivation across the metaplasia-dysplasia-EAC sequence drives the chromosomally unstable, mutator-phenotype genome.
Adaptive Immune Resistance Invasive EAC subsets acquire PD-L1-linked checkpoint programs that enable immune escape.
Dysphagia Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
Weight Loss Tumor burden and impaired oral intake contribute to weight loss.
Show evidence (3 references)
PMID:40874980 SUPPORT Human Clinical
"Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
Establishes Barrett esophagus as the obligate precursor lesion of EAC.
PMID:34503107 SUPPORT Human Clinical
"The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
Anchors recurrent TP53/CDKN2A/ERBB2 lesions as the molecular backbone of the Barrett-EAC progression.
PMID:37298253 SUPPORT Other
"biliary reflux, which causes extensive mutagenesis in the stem cells of the epithelium in the distal esophagus and gastro-esophageal junction"
Implicates biliary (not only acid) reflux-driven mutagenesis of distal esophageal stem cells as an initiating event of Barrett metaplasia.
Chromosomal Instability and Mutator Phenotype
Both histologic subtypes of esophageal carcinoma, and EAC in particular, are dominated by a chromosomally unstable, mutator-phenotype genome: near-universal TP53 inactivation removes DNA-damage-checkpoint control, and accumulating somatic mutations plus large-scale chromosomal structural rearrangements drive the aneuploid, copy-number-driven landscape that resembles the chromosomally unstable variant of gastric adenocarcinoma.
epithelial cell of esophagus CL:0002252 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves epithelial cell of esophagus (CL:0002252). CL:0002252 is a cell type from the Cell Ontology.
DNA repair GO:0006281 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased DNA repair (GO:0006281). GO:0006281 is a biological process from the Gene Ontology. ↓ DECREASED
esophagus UBERON:0001043 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in esophagus (UBERON:0001043). UBERON:0001043 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:38001670 SUPPORT Other
"The accumulation of somatic mutations at the early phase and chromosomal structural rearrangements at relatively later time points contribute to the dynamic and heterogeneous genetic landscape of EAC"
Anchors early somatic mutation plus later chromosomal structural rearrangement as the origin of the chromosomally unstable EAC genome.
PMID:28052061 SUPPORT Human Clinical
"Oesophageal adenocarcinomas strongly resembled the chromosomally unstable"
TCGA shows EAC resembles the chromosomally unstable variant of gastric adenocarcinoma, supporting chromosomal instability as a core EAC mechanism.
Adaptive Immune Resistance
A clinically meaningful subset of advanced esophageal carcinoma (both ESCC and EAC, including Barrett-associated dysplastic and invasive lesions) expresses PD-L1 on tumor cells and tumor-infiltrating immune cells, consistent with a checkpoint-mediated adaptive immune-resistance state targetable with PD-1 blockade.
negative regulation of T cell mediated immunity GO:0002710 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of T cell mediated immunity (GO:0002710). GO:0002710 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (3 references)
PMID:30684971 SUPPORT Human Clinical
"PD-L1 was expressed on 29.9% (113/378) ESCC tumor cells and 40.2% (152/378) tumor-infiltrating immune cells."
Documents a PD-L1-positive checkpoint immune-evasion state in advanced ESCC.
PMID:31724072 SUPPORT Human Clinical
"A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028)."
Supports PD-L1 pathway activation extending across Barrett-associated dysplastic and adenocarcinoma lesions.
PMID:38566201 SUPPORT Human Clinical
"A decreased cellular contexture of regulatory T cells in ESCC TME indicated a potentially favorable pathological response to NAT"
Single-cell profiling shows that a decreased regulatory T cell contexture in the ESCC tumor microenvironment indicates a more favorable pathological response to neoadjuvant chemo-immunotherapy; conversely, a Treg-rich immunosuppressive microenvironment tracks with poorer response, consistent with Treg-mediated adaptive immune resistance.
✶

Histopathology

1
Barrett Esophagus (Precursor Lesion)
Specialized intestinal metaplasia of the distal esophageal mucosa replacing stratified squamous epithelium with columnar epithelium containing goblet cells. The obligate histologic precursor of esophageal adenocarcinoma.
Show evidence (1 reference)
PMID:40874980 SUPPORT Human Clinical
"Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
Defines Barrett esophagus as the histologic precursor lesion specific to the EAC subtype.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Barrett Esophagus (Precursor Lesion)' (from 'Barrett Metaplasia to EAC Sequence') not found in named elements
Pathograph: causal mechanism network for Esophageal Carcinoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Digestive 2
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Odynophagia HP:0032043 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Odynophagia (HP:0032043). HP:0032043 is a phenotype from the Human Phenotype Ontology.
Growth 1
Weight Loss HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
Other 1
Hematemesis HP:0002248 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematemesis (HP:0002248). HP:0002248 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

5
TP53 (Somatic Loss-of-Function Mutation)
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:34503107 SUPPORT Human Clinical
"The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
Identifies TP53 as the dominant recurrent somatic alteration in EAC; comparable predominance is well-documented in ESCC.
PMID:41986343 SUPPORT Other
"is mutated in 85% of ESCC cases, while mutations in NOTCH1,"
Establishes TP53 as the single most frequently mutated gene in ESCC (~85%), confirming its dominance in both histologic subtypes.
CDKN2A (Recurrent Somatic Alteration)
Gene: CDKN2A hgnc:1787 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CDKN2A (hgnc:1787). hgnc:1787 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:34503107 SUPPORT Human Clinical
"The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
Supports CDKN2A as a recurrent somatic alteration disrupting cell-cycle control in esophageal carcinoma.
ERBB2 (HER2) (Somatic Amplification)
Gene: ERBB2 hgnc:3430 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ERBB2 (hgnc:3430). hgnc:3430 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:28052061 SUPPORT Human Clinical
"Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
Supports ERBB2 amplification as a recurrent EAC-predominant driver and biomarker for HER2-directed therapy.
NOTCH1 (Recurrent Somatic Mutation (ESCC))
Gene: NOTCH1 hgnc:7881 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NOTCH1 (hgnc:7881). hgnc:7881 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:41986343 SUPPORT Other
"mutations, including TP53, NOTCH1, MLL2, FAT1, NFE2L2, PIK3CA,"
A combined whole-genome analysis of 704 ESCC samples ranks NOTCH1 among the most common somatic driver mutations in ESCC.
NFE2L2 (Recurrent Somatic Mutation (ESCC))
Gene: NFE2L2 (NRF2) hgnc:7782 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NFE2L2 (NRF2), annotated with NFE2L2 (hgnc:7782). hgnc:7782 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:41986343 SUPPORT Other
"mutations, including TP53, NOTCH1, MLL2, FAT1, NFE2L2, PIK3CA,"
NFE2L2 (NRF2), the master oxidative-stress transcription factor, is among the recurrent somatic driver mutations identified in ESCC by whole-genome sequencing, defining an NRF2-activated ESCC subset.
💊

Medical Actions

5
Esophagectomy
Action: esophagectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is esophagectomy (NCIT:C15357). NCIT:C15357 is a clinical intervention from the NCI Thesaurus. Ontology label: Esophagectomy NCIT:C15357
Surgical resection of the esophagus remains the cornerstone of curative treatment for resectable invasive esophageal carcinoma, typically combined with neoadjuvant chemoradiotherapy.
Show evidence (1 reference)
PMID:28648400 SUPPORT Human Clinical
"Neoadjuvant therapy with chemotherapy or chemoradiotherapy has supplemented surgery as standard treatment of locally advanced oesophageal cancer."
Supports surgery (esophagectomy) plus neoadjuvant therapy as the standard curative-intent platform.
Neoadjuvant Chemoradiotherapy
Action: chemoradiotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemoradiotherapy (NCIT:C94626). NCIT:C94626 is a clinical intervention from the NCI Thesaurus. Ontology label: Chemoradiotherapy NCIT:C94626
Agent: cisplatin CHEBI:27899 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cisplatin (CHEBI:27899). CHEBI:27899 is a therapeutic agent from Chemical Entities of Biological Interest. fluorouracil CHEBI:46345 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses fluorouracil, annotated with 5-fluorouracil (CHEBI:46345). CHEBI:46345 is a therapeutic agent from Chemical Entities of Biological Interest.
Combined chemotherapy and radiation given prior to esophagectomy improves long-term survival in locally advanced resectable esophageal carcinoma.
Show evidence (1 reference)
PMID:28648400 SUPPORT Human Clinical
"Neoadjuvant therapy with chemotherapy or chemoradiotherapy has supplemented surgery as standard treatment of locally advanced oesophageal cancer."
Establishes neoadjuvant chemoradiotherapy as standard of care for locally advanced esophageal carcinoma.
First-Line Pembrolizumab Plus Chemotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pembrolizumab NCIT:C106432 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses pembrolizumab (NCIT:C106432). NCIT:C106432 is a therapeutic agent from the NCI Thesaurus. cisplatin CHEBI:27899 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cisplatin (CHEBI:27899). CHEBI:27899 is a therapeutic agent from Chemical Entities of Biological Interest. fluorouracil CHEBI:46345 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses fluorouracil, annotated with 5-fluorouracil (CHEBI:46345). CHEBI:46345 is a therapeutic agent from Chemical Entities of Biological Interest.
Adding the anti-PD-1 antibody pembrolizumab to first-line fluoropyrimidine-platinum chemotherapy improves overall and progression-free survival in advanced esophageal carcinoma, with the largest benefit in ESCC and in PD-L1 CPS-high disease.
Mechanism Target:
INHIBITS Adaptive Immune Resistance — Pembrolizumab targets PD-1 to reverse checkpoint-mediated immune resistance in advanced esophageal carcinoma.
Show evidence (1 reference)
PMID:34454674 SUPPORT Human Clinical
"Compared with placebo plus chemotherapy, pembrolizumab plus chemotherapy improved overall survival in patients with previously untreated, advanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and overall survival and progression-free survival in patients with oesophageal..."
KEYNOTE-590 establishes first-line pembrolizumab plus chemotherapy as standard of care in advanced esophageal carcinoma.
Adjuvant Nivolumab After Trimodality Therapy
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: nivolumab NCIT:C68814 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses nivolumab (NCIT:C68814). NCIT:C68814 is a therapeutic agent from the NCI Thesaurus.
In patients with resected esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiotherapy, adjuvant nivolumab significantly prolongs disease-free survival.
Mechanism Target:
INHIBITS Adaptive Immune Resistance — Adjuvant nivolumab blocks PD-1 to counteract checkpoint-mediated immune resistance in resected high-risk disease.
Show evidence (1 reference)
PMID:33789008 SUPPORT Human Clinical
"Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo."
CheckMate 577 supports adjuvant PD-1 blockade after trimodality therapy as a new standard of care.
Trastuzumab for HER2-Positive EAC
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: trastuzumab CHEBI:231601 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses trastuzumab (CHEBI:231601). CHEBI:231601 is a therapeutic agent from Chemical Entities of Biological Interest.
HER2-targeted monoclonal antibody therapy is appropriate for the ERBB2-amplified subset of esophageal/gastroesophageal junction adenocarcinoma, biomarker-selected by IHC/FISH testing.
Show evidence (2 references)
PMID:20728210 SUPPORT Human Clinical
"Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer."
ToGA establishes trastuzumab plus chemotherapy as a standard option in HER2-positive advanced gastro-oesophageal junction adenocarcinoma, which overlaps with esophageal adenocarcinoma at the GEJ.
PMID:28052061 SUPPORT Human Clinical
"Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
Anchors the ERBB2/HER2-amplified EAC subset as the biological rationale for trastuzumab eligibility.
🌍

Environmental Factors

4
Tobacco Smoking
exposure to tobacco smoking ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Cigarette smoking is a major modifiable risk factor, especially for ESCC, exposing the esophageal epithelium to carcinogens that cooperate with alcohol in upper aerodigestive carcinogenesis.
Show evidence (1 reference)
PMID:20224883 SUPPORT Human Clinical
"Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
Identifies cigarette smoking as a major ESCC risk factor.
Mechanism Target:
TRIGGERS ESCC Carcinogen-Driven Squamous Transformation — Tobacco carcinogens act on squamous epithelium directly, which is why smoking drives the squamous-cell arm of this disease rather than the adenocarcinoma arm that reflux and obesity feed.
Show evidence (1 reference)
PMID:20224883 SUPPORT Human Clinical
"Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
Names cigarette smoking as a major risk factor for oesophageal squamous cell carcinoma specifically.
Ethanol Exposure
exposure to ethanol ECTO:9000027 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to ethanol (ECTO:9000027). ECTO:9000027 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Named and bound for the chemical (ECTO:9000027, which involves CHEBI ethanol) rather than the drinking behaviour (ECTO:0001082) because the mechanism curated here is ethanol oxidation to acetaldehyde. Renamed from "Alcohol Consumption" so the binding is derivable from the entry's own name.
Alcohol use is a major risk factor for ESCC and acts synergistically with tobacco, with acetaldehyde and ALDH2-dependent susceptibility contributing to mutational burden in esophageal squamous epithelium.
Show evidence (1 reference)
PMID:20224883 SUPPORT Human Clinical
"Acetaldehyde is the most toxic ethanol metabolite in alcohol-associated carcinogenesis"
Identifies acetaldehyde from ethanol metabolism as the proximate carcinogenic mediator.
Mechanism Target:
TRIGGERS ESCC Carcinogen-Driven Squamous Transformation — Ethanol is not itself the carcinogen: it is oxidised to acetaldehyde, which forms DNA adducts in squamous mucosa. That intermediate is why ALDH2 variants that slow acetaldehyde clearance raise risk so sharply.
Show evidence (1 reference)
PMID:20224883 SUPPORT Human Clinical
"Acetaldehyde is the most toxic ethanol metabolite in alcohol-associated carcinogenesis"
Identifies acetaldehyde as the most toxic ethanol metabolite in alcohol-associated carcinogenesis, the intervening species between drinking and squamous transformation.
Chronic Gastroesophageal Reflux Disease
Chronic GERD drives Barrett metaplasia of the distal esophagus and is the principal modifiable upstream exposure for esophageal adenocarcinoma.
Show evidence (1 reference)
PMID:34503107 SUPPORT Human Clinical
"Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
Identifies chronic GERD-driven Barrett metaplasia as the principal upstream risk factor for EAC.
Mechanism Target:
TRIGGERS Barrett Metaplasia to EAC Sequence — Repeated acid and bile exposure drives the columnar metaplasia this node names, which is the adenocarcinoma pathway and mechanistically separate from the squamous one.
Show evidence (1 reference)
PMID:34503107 SUPPORT Human Clinical
"Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
Describes Barrett oesophagus as the metaplastic response of the oesophagus to gastro-oesophageal reflux disease, the sequence this node models.
Western Lifestyle / Obesity
Rising obesity prevalence in Western nations is a principal driver of the epidemiologic shift toward EAC predominance over ESCC.
Show evidence (1 reference)
PMID:37812328 SUPPORT Human Clinical
"In Western nations, more often the United States, there has been a shift from SCC predominance to the majority of new cases of EC being adenocarcinoma. This shift within the United States has largely correlated with a rise in obesity."
Anchors the histology shift to a population-level obesity trend.
Mechanism Target:
PREDISPOSES Barrett Metaplasia to EAC Sequence — Central obesity raises intra-abdominal pressure and reflux, and the epidemiology tracks it: the histological balance in Western countries has shifted from squamous to adenocarcinoma as obesity has risen.
Show evidence (1 reference)
PMID:37812328 SUPPORT Human Clinical
"In Western nations, more often the United States, there has been a shift from SCC predominance to the majority of new cases of EC being adenocarcinoma. This shift within the United States has largely correlated with a rise in obesity."
Reports a shift in Western nations from squamous cell predominance toward adenocarcinoma, the histological shift this exposure accompanies.
📊

Prevalence

1
Worldwide
Annual Incidence 5.0 per 100,000 1–9 per 100,000
GLOBOCAN 2022: an estimated 511,054 new cases and 445,391 deaths globally, with a global age-standardized incidence rate of 5.00 and mortality rate of 4.30 per 100,000. Incidence and mortality are consistently higher in males than females across all world regions, and East Asia and East/Southern Africa carry the highest burden.
Show evidence (1 reference)
PMID:39668405 SUPPORT Human Clinical
"The global ASIR and ASMR for esophageal cancer were 5.00 and 4.30 per 100,000, respectively"
GLOBOCAN 2022 age-standardized incidence rate anchors the worldwide occurrence of esophageal carcinoma.
📊

Related Datasets

4
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma geo:GSE203067
We profiled the transcriptome of 85, 263 single cells from ESCC patients with lymph node metastasis (LNM) and clustered 7, 196 myeloid cells into 18 subclusters including nine for macrophage cells, one for neutrophils, two for monocytes, two for mast cells, one for tolerogenic dendritic cells, one for plasmacytoid dendritic cells and two for conventional dendritic cells. In this study, we not only provides a high-resolution landscape of the tumor, immune and stromal compartments in metastatic lymph node, but also highlights metastatic-specific patterns comparing with primary tumor.
human SINGLE CELL RNA SEQ n=21
PMID:36709495
Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Association of immune related expression profile with sensitivity to neoadjuvant chemotherapy using docetaxel, cisplatin and 5-fluorouracil in esophageal squamous cell carcinoma. geo:GSE225178
Neoadjuvant chemotherapy (NAC) followed by surgery is one of the standard therapeutic approaches for patients with locally advanced esophageal carcinoma in Japan. Recently, JCOG1109 study revealed that NAC with docetaxel, cisplatin and 5-fluorouracil (5-FU) (DCF-NAC) is superior to NAC with cisplatin and 5-FU, and has become the standard preoperative chemotherapy. By using microarray, we have previously investigated expression profiles of endoscopic biopsies of patients with esophageal squamous cell carcinoma (ESCC) before DCF-NAC (preNAC) and identified 17 molecules as predictive biomarkers for pathologically complete response to DCF-NAC.
human MICROARRAY n=44
PMID:37715346
Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Characterization of esophageal squamous cell carcinoma cell lines sensitivity to Palbociclib geo:GSE312063
Background: Esophageal squamous cell carcinoma (eSCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although immune checkpoint inhibitors such as nivolumab, have shown clinical benefit, particularly in patients with high PD-L1 expression, this subgroup represents only a small fraction of eSCC cases. CDK4/6 inhibitors such as palbociclib have only been tested as second-line agents in eSCC, often in combination with EGFR inhibitors, with minimal benefit. Methods: Our study evaluates palbociclib as a first-line therapy in treatment-naive eSCC models. Using a panel of 22 eSCC cell lines with integrated multi-omics and phenotypic assays.
human BULK RNA SEQ n=88
PMID:42215475
Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
WES sequencing of 100 human esophageal carcinoma cases ega:EGAS00001001259
WES sequencing of 100 human esophageal carcinoma cases
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Esophageal Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
🔬

Clinical Trials

2
NCT03189719 PHASE_III COMPLETED
KEYNOTE-590 evaluated pembrolizumab plus fluorouracil-cisplatin versus chemotherapy alone as first-line treatment for advanced esophageal cancer and Siewert type 1 gastro-esophageal junction cancer.
Show evidence (1 reference)
PMID:34454674 SUPPORT Human Clinical
"This trial is registered with ClinicalTrials.gov, NCT03189719, and is closed to recruitment."
Establishes NCT03189719 as the pivotal first-line ESCC immunochemotherapy trial.
NCT02743494 PHASE_III COMPLETED
CheckMate 577 evaluated adjuvant nivolumab versus placebo in resected esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.
Show evidence (1 reference)
PMID:33789008 SUPPORT Human Clinical
"(Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.)"
Anchors CheckMate 577 as the pivotal trial supporting adjuvant nivolumab in resected disease.
{ }

Source YAML

click to show 
name: Esophageal Carcinoma
creation_date: "2026-05-13T00:00:00Z"
description: >-
  Esophageal carcinoma is a heterogeneous epithelial malignancy of the esophagus
  comprising two biologically and epidemiologically distinct histologic
  subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal
  adenocarcinoma (EAC). ESCC dominates globally and is concentrated in East
  Asia, parts of Africa, and along the "esophageal cancer belt", and is driven
  largely by tobacco, alcohol, and other carcinogenic environmental exposures
  acting on stratified squamous mucosa. EAC predominates in Western populations,
  arises almost exclusively from Barrett metaplasia in the setting of chronic
  gastroesophageal reflux and obesity, and resembles chromosomally unstable
  gastric adenocarcinoma molecularly. Both subtypes typically present late with
  dysphagia and weight loss, carry a poor prognosis, and are managed with
  multimodality regimens combining surgery, chemoradiotherapy, and
  PD-1-directed immunotherapy.
category: Complex
categories:
- Gastrointestinal Cancer
- Esophageal Cancer
- Solid Tumor
parents:
- esophageal cancer
- carcinoma
disease_term:
  preferred_term: esophageal carcinoma
  term:
    id: MONDO:0019086
    label: carcinoma of esophagus
has_subtypes:
- name: ESCC
  display_name: Esophageal Squamous Cell Carcinoma
  description: >-
    Squamous-cell histology arising from the stratified squamous mucosa of the
    esophagus. Dominant subtype worldwide; strongly linked to tobacco, alcohol,
    and other environmental carcinogens; molecularly characterized by frequent
    TP53 loss-of-function and recurrent alterations in cell-cycle, squamous
    differentiation, NOTCH, and PI3K/AKT pathways.
  classification: histologic
  evidence:
  - reference: PMID:28052061
    reference_title: Integrated genomic characterization of oesophageal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Beyond known histopathological and epidemiologic distinctions, molecular features differentiated oesophageal squamous cell carcinomas from oesophageal adenocarcinomas."
    explanation: TCGA shows ESCC and EAC are molecularly distinct, supporting the histologic-subtype dichotomy.
- name: EAC
  display_name: Esophageal Adenocarcinoma
  description: >-
    Gland-forming malignancy arising in the distal esophagus from Barrett
    metaplastic mucosa after chronic gastroesophageal reflux. Western-population
    predominant; characterized by chromosomal instability, near-universal TP53
    alteration, and a targetable ERBB2-amplified subset.
  classification: histologic
  evidence:
  - reference: PMID:34503107
    reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
    explanation: Confirms EAC almost universally arises from Barrett metaplasia driven by chronic GERD.
pathophysiology:
- name: ESCC Carcinogen-Driven Squamous Transformation
  description: >-
    In esophageal squamous cell carcinoma, chronic exposure of stratified
    squamous epithelium to tobacco-derived carcinogens and acetaldehyde from
    alcohol metabolism produces DNA damage and mutational burden that selects
    for TP53 loss-of-function and recurrent alterations in cell-cycle, squamous
    differentiation, and NOTCH signaling.
  cell_types:
  - preferred_term: epithelial cell of esophagus
    term:
      id: CL:0002252
      label: epithelial cell of esophagus
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
  locations:
  - preferred_term: esophagus
    term:
      id: UBERON:0001043
      label: esophagus
  evidence:
  - reference: PMID:20224883
    reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
    explanation: Identifies tobacco and alcohol as principal upstream drivers of ESCC carcinogenesis.
  - reference: PMID:28052061
    reference_title: Integrated genomic characterization of oesophageal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
    explanation: Supports distinct ESCC genomic landscape with squamous-lineage transcription-factor amplifications.
  downstream:
  - target: Adaptive Immune Resistance
    description: Expanding ESCC tumors acquire PD-L1-linked checkpoint programs that enable immune escape.
  - target: Dysphagia
    description: Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
  - target: Weight Loss
    description: Tumor burden and impaired oral intake contribute to weight loss.
- name: Barrett Metaplasia to EAC Sequence
  description: >-
    In esophageal adenocarcinoma, chronic gastroesophageal reflux drives
    columnar (Barrett) metaplasia of the distal esophageal mucosa, which
    progresses through dysplasia to invasive adenocarcinoma. The transition is
    accompanied by progressive TP53 inactivation and accumulating chromosomal
    instability with recurrent copy-number changes including ERBB2
    amplification.
  cell_types:
  - preferred_term: epithelial cell of esophagus
    term:
      id: CL:0002252
      label: epithelial cell of esophagus
  biological_processes:
  - preferred_term: epithelial cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030855
      label: epithelial cell differentiation
  locations:
  - preferred_term: esophagus
    term:
      id: UBERON:0001043
      label: esophagus
  evidence:
  - reference: PMID:40874980
    reference_title: "Screening for Barrett Esophagus and Esophageal Adenocarcinoma: Approaches and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
    explanation: Establishes Barrett esophagus as the obligate precursor lesion of EAC.
  - reference: PMID:34503107
    reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
    explanation: Anchors recurrent TP53/CDKN2A/ERBB2 lesions as the molecular backbone of the Barrett-EAC progression.
  - reference: PMID:37298253
    reference_title: "Signaling Pathways in the Pathogenesis of Barrett's Esophagus and Esophageal Adenocarcinoma."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "biliary reflux, which causes extensive mutagenesis in the stem cells of the epithelium in the distal esophagus and gastro-esophageal junction"
    explanation: Implicates biliary (not only acid) reflux-driven mutagenesis of distal esophageal stem cells as an initiating event of Barrett metaplasia.
  downstream:
  - target: Barrett Esophagus (Precursor Lesion)
    description: Columnar (Barrett) metaplasia of the distal esophageal mucosa is the obligate histologic precursor of EAC.
  - target: Chromosomal Instability and Mutator Phenotype
    description: Progressive TP53 inactivation across the metaplasia-dysplasia-EAC sequence drives the chromosomally unstable, mutator-phenotype genome.
  - target: Adaptive Immune Resistance
    description: Invasive EAC subsets acquire PD-L1-linked checkpoint programs that enable immune escape.
  - target: Dysphagia
    description: Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
  - target: Weight Loss
    description: Tumor burden and impaired oral intake contribute to weight loss.
- name: Chromosomal Instability and Mutator Phenotype
  conforms_to: "genome_instability_mutation#Mutator Phenotype and Chromosomal Instability"
  description: >-
    Both histologic subtypes of esophageal carcinoma, and EAC in particular,
    are dominated by a chromosomally unstable, mutator-phenotype genome:
    near-universal TP53 inactivation removes DNA-damage-checkpoint control, and
    accumulating somatic mutations plus large-scale chromosomal structural
    rearrangements drive the aneuploid, copy-number-driven landscape that
    resembles the chromosomally unstable variant of gastric adenocarcinoma.
  cell_types:
  - preferred_term: epithelial cell of esophagus
    term:
      id: CL:0002252
      label: epithelial cell of esophagus
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
  locations:
  - preferred_term: esophagus
    term:
      id: UBERON:0001043
      label: esophagus
  evidence:
  - reference: PMID:38001670
    reference_title: Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The accumulation of somatic mutations at the early phase and chromosomal structural rearrangements at relatively later time points contribute to the dynamic and heterogeneous genetic landscape of EAC"
    explanation: Anchors early somatic mutation plus later chromosomal structural rearrangement as the origin of the chromosomally unstable EAC genome.
  - reference: PMID:28052061
    reference_title: Integrated genomic characterization of oesophageal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Oesophageal adenocarcinomas strongly resembled the chromosomally unstable"
    explanation: TCGA shows EAC resembles the chromosomally unstable variant of gastric adenocarcinoma, supporting chromosomal instability as a core EAC mechanism.
- name: Adaptive Immune Resistance
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    A clinically meaningful subset of advanced esophageal carcinoma (both ESCC
    and EAC, including Barrett-associated dysplastic and invasive lesions)
    expresses PD-L1 on tumor cells and tumor-infiltrating immune cells,
    consistent with a checkpoint-mediated adaptive immune-resistance state
    targetable with PD-1 blockade.
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  evidence:
  - reference: PMID:30684971
    reference_title: "PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PD-L1 was expressed on 29.9% (113/378) ESCC tumor cells and 40.2% (152/378) tumor-infiltrating immune cells."
    explanation: Documents a PD-L1-positive checkpoint immune-evasion state in advanced ESCC.
  - reference: PMID:31724072
    reference_title: "PD-L1 expression in gastroesophageal dysplastic lesions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028)."
    explanation: Supports PD-L1 pathway activation extending across Barrett-associated dysplastic and adenocarcinoma lesions.
  - reference: PMID:38566201
    reference_title: Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A decreased cellular contexture of regulatory T cells in ESCC TME indicated a potentially favorable pathological response to NAT"
    explanation: Single-cell profiling shows that a decreased regulatory T cell contexture in the ESCC tumor microenvironment indicates a more favorable pathological response to neoadjuvant chemo-immunotherapy; conversely, a Treg-rich immunosuppressive microenvironment tracks with poorer response, consistent with Treg-mediated adaptive immune resistance.
phenotypes:
- name: Dysphagia
  description: Progressive difficulty swallowing solids, then liquids, is the most common presenting symptom of esophageal carcinoma due to luminal narrowing by tumor.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
- name: Weight Loss
  description: Unintentional weight loss is a frequent presenting feature, reflecting both impaired oral intake from dysphagia and cancer cachexia.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- name: Odynophagia
  description: Painful swallowing can occur with ulcerated or locally invasive esophageal tumors.
  phenotype_term:
    preferred_term: Odynophagia
    term:
      id: HP:0032043
      label: Odynophagia
- name: Hematemesis
  description: Bleeding from ulcerated esophageal tumor can manifest as hematemesis, particularly with advanced or invasive disease.
  phenotype_term:
    preferred_term: Hematemesis
    term:
      id: HP:0002248
      label: Hematemesis
environmental:
- name: Tobacco Smoking
  influences_mechanisms:
  - target: ESCC Carcinogen-Driven Squamous Transformation
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Tobacco carcinogens act on squamous epithelium directly, which is why
      smoking drives the squamous-cell arm of this disease rather than the
      adenocarcinoma arm that reflux and obesity feed.
    evidence:
    - reference: PMID:20224883
      reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
      explanation: >-
        Names cigarette smoking as a major risk factor for oesophageal
        squamous cell carcinoma specifically.
  description: >-
    Cigarette smoking is a major modifiable risk factor, especially for ESCC,
    exposing the esophageal epithelium to carcinogens that cooperate with
    alcohol in upper aerodigestive carcinogenesis.
  effect: HARMFUL
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  evidence:
  - reference: PMID:20224883
    reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
    explanation: Identifies cigarette smoking as a major ESCC risk factor.
- name: Ethanol Exposure
  influences_mechanisms:
  - target: ESCC Carcinogen-Driven Squamous Transformation
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Ethanol is not itself the carcinogen: it is oxidised to acetaldehyde,
      which forms DNA adducts in squamous mucosa. That intermediate is why
      ALDH2 variants that slow acetaldehyde clearance raise risk so sharply.
    evidence:
    - reference: PMID:20224883
      reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Acetaldehyde is the most toxic ethanol metabolite in alcohol-associated carcinogenesis"
      explanation: >-
        Identifies acetaldehyde as the most toxic ethanol metabolite in
        alcohol-associated carcinogenesis, the intervening species between
        drinking and squamous transformation.
  description: >-
    Alcohol use is a major risk factor for ESCC and acts synergistically with
    tobacco, with acetaldehyde and ALDH2-dependent susceptibility contributing
    to mutational burden in esophageal squamous epithelium.
  notes: >-
    Named and bound for the chemical (ECTO:9000027, which involves CHEBI ethanol)
    rather than the drinking behaviour (ECTO:0001082) because the mechanism curated
    here is ethanol oxidation to acetaldehyde. Renamed from "Alcohol Consumption" so
    the binding is derivable from the entry's own name.
  effect: HARMFUL
  exposure_term:
    preferred_term: exposure to ethanol
    term:
      id: ECTO:9000027
      label: exposure to ethanol
  evidence:
  - reference: PMID:20224883
    reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acetaldehyde is the most toxic ethanol metabolite in alcohol-associated carcinogenesis"
    explanation: Identifies acetaldehyde from ethanol metabolism as the proximate carcinogenic mediator.
- name: Chronic Gastroesophageal Reflux Disease
  influences_mechanisms:
  - target: Barrett Metaplasia to EAC Sequence
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Repeated acid and bile exposure drives the columnar metaplasia this node
      names, which is the adenocarcinoma pathway and mechanistically separate
      from the squamous one.
    evidence:
    - reference: PMID:34503107
      reference_title: "Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
      explanation: >-
        Describes Barrett oesophagus as the metaplastic response of the
        oesophagus to gastro-oesophageal reflux disease, the sequence this
        node models.
  description: >-
    Chronic GERD drives Barrett metaplasia of the distal esophagus and is the
    principal modifiable upstream exposure for esophageal adenocarcinoma.
  effect: HARMFUL
  evidence:
  - reference: PMID:34503107
    reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
    explanation: Identifies chronic GERD-driven Barrett metaplasia as the principal upstream risk factor for EAC.
- name: Western Lifestyle / Obesity
  influences_mechanisms:
  - target: Barrett Metaplasia to EAC Sequence
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Central obesity raises intra-abdominal pressure and reflux, and the
      epidemiology tracks it: the histological balance in Western countries
      has shifted from squamous to adenocarcinoma as obesity has risen.
    evidence:
    - reference: PMID:37812328
      reference_title: "Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In Western nations, more often the United States, there has been a shift from SCC predominance to the majority of new cases of EC being adenocarcinoma. This shift within the United States has largely correlated with a rise in obesity."
      explanation: >-
        Reports a shift in Western nations from squamous cell predominance
        toward adenocarcinoma, the histological shift this exposure
        accompanies.
  description: >-
    Rising obesity prevalence in Western nations is a principal driver of the
    epidemiologic shift toward EAC predominance over ESCC.
  effect: HARMFUL
  evidence:
  - reference: PMID:37812328
    reference_title: "Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In Western nations, more often the United States, there has been a shift from SCC predominance to the majority of new cases of EC being adenocarcinoma. This shift within the United States has largely correlated with a rise in obesity."
    explanation: Anchors the histology shift to a population-level obesity trend.
genetic:
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Somatic Loss-of-Function Mutation
  evidence:
  - reference: PMID:34503107
    reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
    explanation: Identifies TP53 as the dominant recurrent somatic alteration in EAC; comparable predominance is well-documented in ESCC.
  - reference: PMID:41986343
    reference_title: "Esophageal cancer: from pathogenesis to precision therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is mutated in 85% of ESCC cases, while mutations in NOTCH1,"
    explanation: Establishes TP53 as the single most frequently mutated gene in ESCC (~85%), confirming its dominance in both histologic subtypes.
  notes: >-
    Somatic TP53 loss-of-function is the most common recurrent driver event in
    both EAC and ESCC and is closely tied to chromosomal instability across the
    Barrett-dysplasia-adenocarcinoma sequence.
- name: CDKN2A
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  association: Recurrent Somatic Alteration
  evidence:
  - reference: PMID:34503107
    reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
    explanation: Supports CDKN2A as a recurrent somatic alteration disrupting cell-cycle control in esophageal carcinoma.
- name: ERBB2 (HER2)
  gene_term:
    preferred_term: ERBB2
    term:
      id: hgnc:3430
      label: ERBB2
  association: Somatic Amplification
  evidence:
  - reference: PMID:28052061
    reference_title: Integrated genomic characterization of oesophageal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
    explanation: Supports ERBB2 amplification as a recurrent EAC-predominant driver and biomarker for HER2-directed therapy.
  notes: >-
    ERBB2 amplification defines a clinically actionable subset of EAC eligible
    for HER2-directed therapy.
- name: NOTCH1
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  association: Recurrent Somatic Mutation (ESCC)
  evidence:
  - reference: PMID:41986343
    reference_title: "Esophageal cancer: from pathogenesis to precision therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "mutations, including TP53, NOTCH1, MLL2, FAT1, NFE2L2, PIK3CA,"
    explanation: A combined whole-genome analysis of 704 ESCC samples ranks NOTCH1 among the most common somatic driver mutations in ESCC.
  notes: >-
    NOTCH1 loss-of-function mutations are recurrent ESCC drivers (~10-17% of
    cases) and also expand as clones in histologically normal esophageal
    epithelium, marking NOTCH1 as an early squamous-lineage event distinct from
    the ERBB2/chromosomal-instability program of EAC.
- name: NFE2L2
  gene_term:
    preferred_term: NFE2L2 (NRF2)
    term:
      id: hgnc:7782
      label: NFE2L2
  association: Recurrent Somatic Mutation (ESCC)
  evidence:
  - reference: PMID:41986343
    reference_title: "Esophageal cancer: from pathogenesis to precision therapies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "mutations, including TP53, NOTCH1, MLL2, FAT1, NFE2L2, PIK3CA,"
    explanation: NFE2L2 (NRF2), the master oxidative-stress transcription factor, is among the recurrent somatic driver mutations identified in ESCC by whole-genome sequencing, defining an NRF2-activated ESCC subset.
  notes: >-
    Activating NFE2L2 (or inactivating KEAP1/CUL3) mutations constitutively
    switch on the NRF2 antioxidant program, promoting survival and therapy
    resistance predominantly in ESCC.
histopathology:
- name: Barrett Esophagus (Precursor Lesion)
  description: >-
    Specialized intestinal metaplasia of the distal esophageal mucosa replacing
    stratified squamous epithelium with columnar epithelium containing goblet
    cells. The obligate histologic precursor of esophageal adenocarcinoma.
  subtype: EAC
  evidence:
  - reference: PMID:40874980
    reference_title: "Screening for Barrett Esophagus and Esophageal Adenocarcinoma: Approaches and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
    explanation: Defines Barrett esophagus as the histologic precursor lesion specific to the EAC subtype.
treatments:
- name: Esophagectomy
  description: >-
    Surgical resection of the esophagus remains the cornerstone of curative
    treatment for resectable invasive esophageal carcinoma, typically combined
    with neoadjuvant chemoradiotherapy.
  treatment_term:
    preferred_term: esophagectomy
    term:
      id: NCIT:C15357
      label: Esophagectomy
  evidence:
  - reference: PMID:28648400
    reference_title: Oesophageal cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neoadjuvant therapy with \nchemotherapy or chemoradiotherapy has supplemented surgery as standard treatment \nof locally advanced oesophageal cancer."
    explanation: Supports surgery (esophagectomy) plus neoadjuvant therapy as the standard curative-intent platform.
- name: Neoadjuvant Chemoradiotherapy
  description: >-
    Combined chemotherapy and radiation given prior to esophagectomy improves
    long-term survival in locally advanced resectable esophageal carcinoma.
  treatment_term:
    preferred_term: chemoradiotherapy
    term:
      id: NCIT:C94626
      label: Chemoradiotherapy
    therapeutic_agent:
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
    - preferred_term: fluorouracil
      term:
        id: CHEBI:46345
        label: 5-fluorouracil
  evidence:
  - reference: PMID:28648400
    reference_title: Oesophageal cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neoadjuvant therapy with \nchemotherapy or chemoradiotherapy has supplemented surgery as standard treatment \nof locally advanced oesophageal cancer."
    explanation: Establishes neoadjuvant chemoradiotherapy as standard of care for locally advanced esophageal carcinoma.
- name: First-Line Pembrolizumab Plus Chemotherapy
  description: >-
    Adding the anti-PD-1 antibody pembrolizumab to first-line
    fluoropyrimidine-platinum chemotherapy improves overall and
    progression-free survival in advanced esophageal carcinoma, with the
    largest benefit in ESCC and in PD-L1 CPS-high disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pembrolizumab
      term:
        id: NCIT:C106432
        label: Pembrolizumab
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
    - preferred_term: fluorouracil
      term:
        id: CHEBI:46345
        label: 5-fluorouracil
  target_mechanisms:
  - target: Adaptive Immune Resistance
    treatment_effect: INHIBITS
    description: Pembrolizumab targets PD-1 to reverse checkpoint-mediated immune resistance in advanced esophageal carcinoma.
  evidence:
  - reference: PMID:34454674
    reference_title: "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with placebo plus chemotherapy, pembrolizumab plus \nchemotherapy improved overall survival in patients with previously untreated, \nadvanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and \noverall survival and progression-free survival in patients with oesophageal \nsquamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients \nregardless of histology"
    explanation: KEYNOTE-590 establishes first-line pembrolizumab plus chemotherapy as standard of care in advanced esophageal carcinoma.
- name: Adjuvant Nivolumab After Trimodality Therapy
  description: >-
    In patients with resected esophageal or gastroesophageal junction cancer
    who have residual pathologic disease after neoadjuvant chemoradiotherapy,
    adjuvant nivolumab significantly prolongs disease-free survival.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: nivolumab
      term:
        id: NCIT:C68814
        label: Nivolumab
  target_mechanisms:
  - target: Adaptive Immune Resistance
    treatment_effect: INHIBITS
    description: Adjuvant nivolumab blocks PD-1 to counteract checkpoint-mediated immune resistance in resected high-risk disease.
  evidence:
  - reference: PMID:33789008
    reference_title: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo."
    explanation: CheckMate 577 supports adjuvant PD-1 blockade after trimodality therapy as a new standard of care.
- name: Trastuzumab for HER2-Positive EAC
  description: >-
    HER2-targeted monoclonal antibody therapy is appropriate for the
    ERBB2-amplified subset of esophageal/gastroesophageal junction
    adenocarcinoma, biomarker-selected by IHC/FISH testing.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: trastuzumab
      term:
        id: CHEBI:231601
        label: trastuzumab
  evidence:
  - reference: PMID:20728210
    reference_title: "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trastuzumab in combination with chemotherapy can be considered \nas a new standard option for patients with HER2-positive advanced gastric or \ngastro-oesophageal junction cancer."
    explanation: ToGA establishes trastuzumab plus chemotherapy as a standard option in HER2-positive advanced gastro-oesophageal junction adenocarcinoma, which overlaps with esophageal adenocarcinoma at the GEJ.
  - reference: PMID:28052061
    reference_title: Integrated genomic characterization of oesophageal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
    explanation: Anchors the ERBB2/HER2-amplified EAC subset as the biological rationale for trastuzumab eligibility.
clinical_trials:
- name: NCT03189719
  phase: PHASE_III
  status: COMPLETED
  description: >-
    KEYNOTE-590 evaluated pembrolizumab plus fluorouracil-cisplatin versus
    chemotherapy alone as first-line treatment for advanced esophageal cancer
    and Siewert type 1 gastro-esophageal junction cancer.
  evidence:
  - reference: PMID:34454674
    reference_title: "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This trial is registered with ClinicalTrials.gov, \nNCT03189719, and is closed to recruitment."
    explanation: Establishes NCT03189719 as the pivotal first-line ESCC immunochemotherapy trial.
- name: NCT02743494
  phase: PHASE_III
  status: COMPLETED
  description: >-
    CheckMate 577 evaluated adjuvant nivolumab versus placebo in resected
    esophageal or gastroesophageal junction cancer with residual pathologic
    disease after neoadjuvant chemoradiotherapy.
  evidence:
  - reference: PMID:33789008
    reference_title: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.)"
    explanation: Anchors CheckMate 577 as the pivotal trial supporting adjuvant nivolumab in resected disease.
prevalence:
- population: Worldwide
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 5.0
  notes: >-
    GLOBOCAN 2022: an estimated 511,054 new cases and 445,391 deaths globally,
    with a global age-standardized incidence rate of 5.00 and mortality rate of
    4.30 per 100,000. Incidence and mortality are consistently higher in males
    than females across all world regions, and East Asia and East/Southern
    Africa carry the highest burden.
  evidence:
  - reference: PMID:39668405
    reference_title: "Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The global ASIR and ASMR for esophageal cancer were 5.00 and 4.30 per 100,000, respectively"
    explanation: GLOBOCAN 2022 age-standardized incidence rate anchors the worldwide occurrence of esophageal carcinoma.
datasets:
- accession: geo:GSE203067
  title: Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma
  description: We profiled the transcriptome of 85, 263 single cells from ESCC patients with lymph node metastasis (LNM) and clustered 7, 196 myeloid cells into 18 subclusters including nine for macrophage cells, one for neutrophils, two for monocytes, two for mast cells, one for tolerogenic dendritic cells, one for plasmacytoid dendritic cells and two for conventional dendritic cells. In this study, we not only provides a high-resolution landscape of the tumor, immune and stromal compartments in metastatic lymph node, but also highlights metastatic-specific patterns comparing with primary tumor.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 21
  publication: PMID:36709495
  notes: Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE225178
  title: Association of immune related expression profile with sensitivity to neoadjuvant chemotherapy using docetaxel, cisplatin and 5-fluorouracil in esophageal squamous cell carcinoma.
  description: Neoadjuvant chemotherapy (NAC) followed by surgery is one of the standard therapeutic approaches for patients with locally advanced esophageal carcinoma in Japan. Recently, JCOG1109 study revealed that NAC with docetaxel, cisplatin and 5-fluorouracil (5-FU) (DCF-NAC) is superior to NAC with cisplatin and 5-FU, and has become the standard preoperative chemotherapy. By using microarray, we have previously investigated expression profiles of endoscopic biopsies of patients with esophageal squamous cell carcinoma (ESCC) before DCF-NAC (preNAC) and identified 17 molecules as predictive biomarkers for pathologically complete response to DCF-NAC.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 44
  publication: PMID:37715346
  notes: Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE312063
  title: Characterization of esophageal squamous cell carcinoma cell lines sensitivity to Palbociclib
  description: 'Background: Esophageal squamous cell carcinoma (eSCC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. Although immune checkpoint inhibitors such as nivolumab, have shown clinical benefit, particularly in patients with high PD-L1 expression, this subgroup represents only a small fraction of eSCC cases. CDK4/6 inhibitors such as palbociclib have only been tested as second-line agents in eSCC, often in combination with EGFR inhibitors, with minimal benefit. Methods: Our study evaluates palbociclib as a first-line therapy in treatment-naive eSCC models. Using a panel of 22 eSCC cell lines with integrated multi-omics and phenotypic assays.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 88
  publication: PMID:42215475
  notes: Identified by GEO DataSets index search for Esophageal Carcinoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001001259
  title: WES sequencing of 100 human esophageal carcinoma cases
  description: WES sequencing of 100 human esophageal carcinoma cases
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Esophageal Carcinoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
📚

References & Deep Research

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 57 citations 2026-07-05T19:05:26.568101

1. Disease Information

Overview

Esophageal carcinoma (EC) is a highly aggressive malignancy of the esophagus and one of the most lethal cancers worldwide, with approximately 511,054 new cases and 445,391 deaths globally in 2022 (qi2024globalesophagealcancer pages 1-2). It is the seventh leading cause of cancer-related mortality globally, with 5-year survival rates of only 10–30% (zhang2026esophagealcancerfrom pages 1-2). EC encompasses two principal histological subtypes with distinct epidemiological, etiological, and molecular profiles: esophageal squamous cell carcinoma (ESCC), accounting for approximately 80% of cases globally, and esophageal adenocarcinoma (EAC), whose incidence is rising in Western countries (zhang2026esophagealcancerfrom pages 1-2, sheikh2023currentstatusand pages 15-16).

Key Identifiers

  • ICD-10: C15 (Malignant neoplasm of esophagus); C15.0–C15.9 for subsites
  • ICD-11: 2B70 (Malignant neoplasms of oesophagus)
  • MeSH: D004938 (Esophageal Neoplasms)
  • MONDO: MONDO_0019086 (carcinoma of esophagus); MONDO_0005580 (esophageal squamous cell carcinoma); MONDO_0005028 (esophageal adenocarcinoma) (OpenTargets Search: esophageal carcinoma)
  • OMIM: Not a single-gene Mendelian disorder; ESCC/EAC arise from complex multifactorial causes

Common Synonyms

Esophageal cancer, oesophageal carcinoma, cancer of the esophagus, esophageal malignancy, gullet cancer.

Data Sources

Information is derived from aggregated disease-level resources including GLOBOCAN, the Global Burden of Disease (GBD) Study, SEER, TCGA, and published clinical/epidemiological literature.

2. Etiology

Disease Causal Factors

ESCC and EAC have distinct etiological pathways. ESCC develops through a multistep progression from normal squamous epithelium through basal cell hyperplasia and dysplasia to carcinoma, driven by chronic mucosal irritation. EAC evolves from Barrett's esophagus (BE) induced by chronic gastroesophageal reflux disease (GERD), following a stepwise progression: GERD → BE → low-grade dysplasia → high-grade dysplasia → adenocarcinoma (zhang2026esophagealcancerfrom pages 1-2, li2023molecularbiologyand pages 1-2).

Risk Factors

Genetic Risk Factors

  • TP53 mutations are the most frequently altered gene in ESCC (~90% of patients) and are prevalent in EAC, with 46% of BE progressors carrying TP53 mutations compared to 5% of nonprogressors (zhang2026esophagealcancerfrom pages 6-7).
  • CDKN2A inactivation via promoter methylation is detected in nearly all individuals developing dysplasia (zhang2026esophagealcancerfrom pages 9-10).
  • ADH1B polymorphisms (alcohol dehydrogenase 1B) modify acetaldehyde exposure and alcohol-related carcinogenic risk, representing a key genetic susceptibility marker (OpenTargets Search: esophageal carcinoma).
  • Susceptibility loci include variants in CTLA-4, SLC39A6, PLCE1, FOXF, BARX1, and ABCC5 (zhang2026esophagealcancerfrom pages 2-3, li2023molecularbiologyand pages 6-8).
  • Hereditary conditions: Tylosis (focal non-epidermolytic palmoplantar keratoderma) is strongly associated with ESCC risk.

Environmental Risk Factors

  • ESCC: Alcohol consumption, tobacco/opium smoking, dietary carcinogens (nitrosamines), hot beverages, micronutrient deficiencies, betel quid chewing, poor oral hygiene, low socioeconomic status (zhang2026esophagealcancerfrom pages 1-2, sheikh2023currentstatusand pages 15-16, liu2023epidemiologyofesophageal pages 8-9).
  • EAC: Obesity, GERD, smoking, male sex, Caucasian ethnicity, high BMI (li2023molecularbiologyand pages 1-2, sheikh2023currentstatusand pages 15-16).
  • In 2019, smoking accounted for 50.1% of DALYs for EC in males and 11.3% in females; alcohol use accounted for 29.6% in males and 5.1% in females; high BMI accounted for 18.8% in males and 19.3% in females (ilic2024globalburdenof pages 6-10).

Protective Factors

  • Diets rich in fruits and vegetables reduce risk: low-fruit diet accounted for 10.1–12.6% of DALYs (ilic2024globalburdenof pages 6-10).
  • Helicobacter pylori infection has been paradoxically associated with reduced EAC risk.
  • Aspirin and proton pump inhibitor use show chemoprevention potential for EAC (sheikh2023currentstatusand pages 15-16).

Gene-Environment Interactions

ADH1B genetic variants interact with alcohol exposure to modulate acetaldehyde accumulation and carcinogenic risk, particularly in East Asian populations (OpenTargets Search: esophageal carcinoma). Tobacco smoke exposure combined with TP53 polymorphisms significantly increases ESCC risk (zhang2026esophagealcancerfrom pages 2-3).

3. Phenotypes

Symptoms and Clinical Signs

  • Dysphagia (progressive, initially to solids then liquids) — HP:0002015
  • Odynophagia (painful swallowing) — HP:0200136
  • Unintended weight loss — HP:0001824
  • Chest pain/retrosternal discomfort — HP:0100749
  • Hoarseness (recurrent laryngeal nerve involvement) — HP:0001609
  • Chronic cough — HP:0012735
  • Hematemesis/melena (GI bleeding) — HP:0002239
  • Fatigue — HP:0012378
  • Iron deficiency anemia — HP:0001891

Phenotype Characteristics

  • Age of onset: Predominantly adult-onset (>50 years), with peak incidence in the 60–70 age group (ilic2024globalburdenof pages 4-6).
  • Severity: Generally severe; most patients present at advanced stages.
  • Progression: Progressive; early-stage disease is often asymptomatic.
  • Frequency: Dysphagia is present in >90% of symptomatic patients at diagnosis.

Quality of Life Impact

EC significantly impairs quality of life through dysphagia, nutritional compromise, and treatment-related morbidity. The SANO trial demonstrated that active surveillance after complete clinical response to chemoradiotherapy showed noninferior overall survival and better short-term quality of life compared to surgery at 2 years (fick2024immunotherapyforresectable pages 9-10).

4. Genetic/Molecular Information

Key Somatic Mutations (by subtype)

  • ESCC: TP53 (~90%), NOTCH1, NFE2L2/KEAP1, KMT2D, PIK3CA, CDKN2A, FBXW7, EP300 (zhang2026esophagealcancerfrom pages 2-3, zhang2026esophagealcancerfrom pages 6-7).
  • EAC: TP53, SMAD4, CDKN2A, ARID1A with frequent amplifications of ERBB2 (21.8%), CCNE1 (12.6%), GATA4 (10.3%), and KRAS (10.3%) (zhang2026esophagealcancerfrom pages 9-10, li2023molecularbiologyand pages 6-8).

Pathogenic Variants

  • TP53 mutations are predominantly missense/nonsense, occurring throughout the DNA-binding domain; somatic origin in tumors; associated with genomic instability and impaired apoptosis (zhang2026esophagealcancerfrom pages 6-7).
  • CDKN2A inactivation occurs through promoter hypermethylation, homozygous deletion, or LOH; detectable in nearly all dysplasia cases (zhang2026esophagealcancerfrom pages 9-10).
  • ERBB2 amplification in EAC (HER2+) occurs in 15–29% of cases and is an FDA-approved companion diagnostic for trastuzumab therapy (rai2023biomarkersforearly pages 8-9).
  • Tumor mutation burden (TMB) in ESCC cell lines ranges from 48.7 to 70.4 mutations/Mb, with signature 3 (homologous recombination deficiency) being significantly enriched (zhang2025thegenomiclandscape pages 4-7).

Epigenetic Information

  • Genome-wide hypomethylation in cancer tissues and promoter hypermethylation-mediated silencing of tumor suppressor genes (CDKN2A, APC) are characteristic (zhang2026esophagealcancerfrom pages 8-9, zhang2026esophagealcancerfrom pages 9-10).
  • APC promoter hypermethylation is observed in up to 92% of adenocarcinomas (zhang2026esophagealcancerfrom pages 9-10).
  • MicroRNA dysregulation and DNA methylation patterns vary with each phase of BE, LGD, HGD, early EAC, and invasive EAC (li2023molecularbiologyand pages 16-17).
  • RNA m6A demethylation affecting LINC00022 and DNMT1-microRNA126 circuits contribute to growth via ADAM9-EGFR-AKT signaling (zhang2026esophagealcancerfrom pages 30-31).
  • A core gene regulatory network involving TP63, SOX2, and KLF5 regulates chromatin accessibility in ESCC (zhang2026esophagealcancerfrom pages 9-10).

Chromosomal Abnormalities

  • Chromosomal instability (CIN) is a hallmark of both subtypes. Gene amplifications are frequent in 57% of EAC cases (zhang2026esophagealcancerfrom pages 9-10).
  • Copy number variations affect SOX2, NFE2L2, and CDKN2A, progressively accumulating from early dysplasia stages (zhang2026esophagealcancerfrom pages 8-9).
  • LOH at APC locus and structural variations affecting CDKN2A and NOTCH1 are recurrent (zhang2026esophagealcancerfrom pages 9-10).

The following table summarizes key disease-target associations from OpenTargets and literature:

Target Gene Symbol Disease Subtype (ESCC/EAC/Both) Association Score Key Role/Function Therapeutic Relevance Clinical Stage
PDCD1 (PD-1) Both; especially ESCC 0.608 (carcinoma of esophagus); 0.607 (ESCC) Immune checkpoint receptor on T cells; central mediator of T-cell exhaustion in the tumor microenvironment Established biomarker/target for anti-PD-1 immunotherapy; anti-PD-1 plus platinum-based chemotherapy is standard first-line in advanced disease; adjuvant nivolumab improves DFS after neoadjuvant CRT and surgery Approved (OpenTargets approval evidence; nivolumab/pembrolizumab clinical use) (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 21-21, jazieh2024advancesinimmunotherapy pages 1-3)
TP53 Both 0.539 (carcinoma of esophagus); 0.422 (ESCC) Master tumor suppressor controlling DNA-damage response, apoptosis, and genomic stability; most frequently altered driver in EC Primarily prognostic/biologic rather than directly actionable; informs pathogenesis, progression, and resistance biology Biomarker / investigational target (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 6-7, zhang2026esophagealcancerfrom pages 2-3)
ADH1B Mainly ESCC / susceptibility across carcinoma of esophagus 0.530 (carcinoma of esophagus) Alcohol metabolism enzyme; inherited variation modifies acetaldehyde exposure and alcohol-related carcinogenic risk Risk stratification and prevention relevance rather than direct tumor targeting Genetic susceptibility marker (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 1-2)
NFE2L2 (NRF2) Predominantly ESCC 0.522 (carcinoma of esophagus) Oxidative-stress transcriptional program; pathway activation supports survival, detoxification, and therapy resistance Candidate target for resistant ESCC biology; pathway status may guide future precision strategies Preclinical / investigational (OpenTargets Search: esophageal carcinoma, zhang2025thegenomiclandscape pages 4-7, zhang2026esophagealcancerfrom pages 6-7)
EGFR Both; more emphasized in ESCC and subset of EAC 0.512 (carcinoma of esophagus); 0.454 (ESCC) Receptor tyrosine kinase driving proliferation, survival, and invasion Overexpressed in a subset; cetuximab and EGFR-directed approaches studied, but clinical benefit has been inconsistent Investigational / limited clinical utility (OpenTargets Search: esophageal carcinoma, rai2023biomarkersforearly pages 8-9)
FGFR1 Predominantly ESCC / carcinoma of esophagus 0.511 (carcinoma of esophagus) RTK signaling contributor; copy-number gain/amplification in subsets Potential actionable amplification in selected tumors; not standard of care Investigational (OpenTargets Search: esophageal carcinoma)
ERBB2 (HER2) Predominantly EAC 0.503 (carcinoma of esophagus); 0.457 (EAC) RTK amplified in a molecular subset of EAC; promotes oncogenic signaling and chromosomal-instability phenotype Established predictive biomarker; trastuzumab-based therapy for HER2-positive disease; companion diagnostics required Approved in HER2-positive adenocarcinoma (OpenTargets Search: esophageal carcinoma, rai2023biomarkersforearly pages 8-9, zhang2026esophagealcancerfrom pages 2-3)
MTOR Both / carcinoma of esophagus 0.499 (carcinoma of esophagus) Central kinase in PI3K-AKT-mTOR signaling controlling growth, metabolism, and survival Pathway is biologically important, but mTOR inhibitors are not standard therapy in EC Investigational (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 6-7)
CDKN2A Both; especially Barrett's/EAC evolution and ESCC cell-cycle dysregulation 0.696 (esophageal disorder) Tumor suppressor controlling G1/S checkpoint; inactivation/loss is an early event in progression Strong biomarker of progression biology; informs early carcinogenesis and possible prevention/risk models Biomarker / investigational (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 6-7, zhang2026esophagealcancerfrom pages 9-10)
PIK3CA Both 0.658 (esophageal disorder) Catalytic PI3K subunit; activates PI3K-AKT signaling, promoting proliferation, survival, invasion, and metastasis Actionable in principle; pathway inhibitors are relevant in basket/precision-oncology settings, but not routine EC standard Investigational / precision-oncology candidate (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 6-7)
NOTCH1 Predominantly ESCC, but also implicated in EAC evolution Not numerically listed in OpenTargets top rows here Context-dependent driver in squamous epithelium; mutation/activation affects lineage fitness, angiogenesis, and tumor progression Valuable biologic stratifier; no standard NOTCH-directed EC therapy Investigational (zhang2026esophagealcancerfrom pages 6-7, zhang2026esophagealcancerfrom pages 8-9, zhang2025thegenomiclandscape pages 4-7)
SMAD4 Predominantly EAC 0.645 (esophageal disorder) TGF-β pathway tumor suppressor; recurrently altered in EAC and linked to progression from Barrett's neoplasia Biomarker of aggressive biology and progression; not yet a standard direct therapeutic target Biomarker / investigational (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 8-9, li2023molecularbiologyand pages 6-8)
CD274 (PD-L1) Predominantly ESCC but relevant to both 0.478 (ESCC) Ligand for PD-1; key immune-evasion marker within inflamed tumors and myeloid-rich microenvironments FDA-approved companion/selection biomarker for checkpoint blockade in some settings; expression associated with immunotherapy stratification Approved companion biomarker / therapeutic axis (OpenTargets Search: esophageal carcinoma, rai2023biomarkersforearly pages 8-9, chen2025singlecellatlasof pages 5-6)
ARID1A Mainly EAC / esophageal disorder 0.622 (esophageal disorder) Chromatin-remodeling tumor suppressor; contributes to epigenetic dysregulation and genomic instability Emerging biomarker for molecular subclassification and synthetic-lethality concepts; not standard EC target Investigational (OpenTargets Search: esophageal carcinoma, zhang2026esophagealcancerfrom pages 2-3)

Table: This table summarizes major disease-target associations for esophageal carcinoma by integrating OpenTargets association scores with recent literature on subtype biology and therapeutic relevance. It is useful for prioritizing biomarkers and targets across ESCC and EAC, including established immunotherapy and HER2-directed axes as well as investigational pathways.

5. Environmental Information

Environmental Factors

Environmental carcinogens include nitrosamines from dietary sources, air pollution, and occupational exposures. Chronic acid and bile reflux damage the esophageal epithelium, generating reactive oxygen species causing DNA double-strand breaks (maslenkina2023signalingpathwaysin pages 14-16). Nitrite exposure and high-fat diets are additional contributing factors (zhang2026esophagealcancerfrom pages 6-7).

Lifestyle Factors

Tobacco smoking and alcohol consumption are the dominant modifiable risk factors for ESCC, causing ~90% of cases in the US and Western countries (jiang2023globaltrendsin pages 12-13). Obesity is a primary risk factor for EAC. Hot beverage consumption, poor oral hygiene, and sedentary lifestyle contribute to risk (liu2023epidemiologyofesophageal pages 8-9).

Infectious Agents

  • HPV (Human Papillomavirus): Circulating HPV DNA is associated with disease severity in some ESCC cohorts (rai2023biomarkersforearly pages 6-8).
  • EBV (Epstein-Barr Virus): EBV status is under investigation as a biomarker for predicting immunotherapy response (fick2024immunotherapyforresectable pages 4-5).

6. Mechanism / Pathophysiology

Molecular Pathways

  • PI3K/AKT pathway: Overactivation drives cell proliferation, survival, invasion, and metastasis (zhang2026esophagealcancerfrom pages 6-7).
  • Notch signaling: NOTCH1 mutations provide competitive advantage in normal epithelium; overactivation in ESCC promotes angiogenesis through VEGF, ANGPT2, and CXCL1 upregulation (zhang2026esophagealcancerfrom pages 6-7, zhang2026esophagealcancerfrom pages 8-9). KEGG: hsa04330.
  • NRF2/KEAP1 pathway: NRF2 pathway activation (42.9% mutation rate in ESCC cell lines) causes oxidative stress-related DNA damage in neighboring cells (zhang2025thegenomiclandscape pages 4-7, zhang2026esophagealcancerfrom pages 6-7). GO:0006979 (response to oxidative stress).
  • Hippo, RTK-Ras, and Wnt pathways showed mutations across all ESCC cell lines analyzed (zhang2025thegenomiclandscape pages 4-7).
  • NF-κB signaling: Activated by deoxycholic acid in Barrett's esophagus; IL-6/STAT3 signaling mediates apoptotic resistance (maslenkina2023signalingpathwaysin pages 14-16).
  • VEGF signaling: Induces epithelial-to-mesenchymal transition (EMT) (maslenkina2023signalingpathwaysin pages 14-16).

Cellular Processes

  • Apoptosis evasion: TP53 loss impairs apoptotic signaling (GO:0006915).
  • Cell cycle dysregulation: CDKN2A loss leads to loss of G1/S checkpoint and cell over-proliferation (GO:0007049) (zhang2026esophagealcancerfrom pages 6-7).
  • Epithelial-mesenchymal transition (EMT): Key for invasion and metastasis (GO:0001837).
  • Angiogenesis: NOTCH-mediated upregulation of VEGF and ANGPT2 (GO:0001525) (zhang2026esophagealcancerfrom pages 8-9).

Immune System Involvement

The tumor microenvironment shifts from early immune surveillance dominated by CD8+ T cells and NK cells to later immunosuppressive conditions characterized by M2 tumor-associated macrophages, regulatory T cells, myeloid-derived suppressor cells (MDSCs), T-cell exhaustion, and cancer-associated fibroblast (CAF) formation (zhang2026esophagealcancerfrom pages 6-7). Single-cell RNA sequencing has identified CXCL13+CD8+ exhausted T cells as predictors of response to neoadjuvant immunochemotherapy (ji2024singlecellprofilingof pages 1-2). PD-L1+ tumor-associated macrophages correlate with clinical benefit from immunotherapy, and CD39-expressing tumor-infiltrating T cells are associated with improved survival and immunotherapy response (chen2025singlecellatlasof pages 5-6, chen2025singlecellatlasof pages 2-3). SPP1+ macrophages have been identified as key drivers of resistance to neoadjuvant chemoimmunotherapy (ji2024singlecellprofilingof pages 1-2).

Advanced Technologies — Single-Cell and Spatial Transcriptomics

Mass cytometry analysis of over 10 million cells from 25 ESCC tumors revealed a compartmentalized immune landscape with reproducible paucity of CD4+ and CD8+ central memory T cells (TCM) in tumor sites (chen2025singlecellatlasof pages 2-3). Single-cell profiling identified 14 major cell subsets including cancer, immune, and stromal cells, with cancer cell differentiation status correlating with treatment response (ji2024singlecellprofilingof pages 1-2). Spatial transcriptomics revealed metastasis-related regions with surrounding vasculature, suggesting new blood vessel recruitment is essential for ESCC metastasis (guo2025singlecellrnasequencing pages 3-3). Two CAF subtypes were identified: extracellular matrix CAFs (eCAFs) and inflammatory CAFs (iCAFs) (yin2025singlecelltranscriptomicanalysis pages 1-2, yin2025singlecelltranscriptomicanalysis pages 14-15).

7. Anatomical Structures Affected

Organ Level

  • Primary organ: Esophagus (UBERON:0001043)
  • ESCC: Upper and middle esophagus
  • EAC: Lower/distal esophagus and gastroesophageal junction
  • Secondary involvement: Lymph nodes (regional metastasis), liver, lung, kidney, adrenal gland (distant metastasis) (zhang2026esophagealcancerfrom pages 2-3)
  • Body systems: Digestive system (UBERON:0001007)

Tissue and Cell Level

  • ESCC: Squamous epithelium (UBERON:0006914); squamous epithelial cells (CL:0000076)
  • EAC: Columnar epithelium with intestinal metaplasia (Barrett's esophagus)
  • Cell types involved: Epithelial cells, CD8+ T cells, CD4+ T cells, regulatory T cells (CL:0000815), NK cells, macrophages (CL:0000235), dendritic cells, CAFs, endothelial cells, pericytes, MDSCs (zhang2026esophagealcancerfrom pages 2-3, chen2025singlecellatlasof pages 2-3)

Subcellular Level

  • Nucleus (GO:0005634) — genomic instability and TP53 dysfunction
  • Mitochondria — metabolic reprogramming
  • Cell membrane — receptor tyrosine kinases (EGFR, HER2, FGFR)

8. Temporal Development

Onset

  • Typical age: Adult-onset, predominantly 50–70 years, with peak incidence in the 60–70 age group (ilic2024globalburdenof pages 4-6).
  • Onset pattern: Insidious; early-stage disease is frequently asymptomatic.

Progression

  • ESCC stages: Normal epithelium → basal cell hyperplasia → low-grade intraepithelial neoplasia → high-grade intraepithelial neoplasia → invasive carcinoma (zhang2026esophagealcancerfrom pages 1-2).
  • EAC stages: Normal → GERD → Barrett's esophagus → LGD → HGD → EAC (li2023molecularbiologyand pages 1-2).
  • Staging: AJCC TNM staging system (8th edition) incorporating T (tumor depth), N (nodal status), M (metastasis), grade, and location.
  • Progression rate: Variable; some Barrett's esophagus patients progress rapidly while others remain stable. TP53 mutations in BE progressors (46%) vs. nonprogressors (5%) serve as an early predictive marker (zhang2026esophagealcancerfrom pages 6-7).
  • Disease course: Progressive without treatment; chronic, often fatal.

9. Inheritance and Population

Epidemiology

The global epidemiological burden of esophageal cancer is summarized in the following table:

Metric Value Year/Source
Global new cases 511,054 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
Global deaths 445,391 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
Age-standardized incidence rate 5.00 per 100,000 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
Age-standardized mortality rate 4.30 per 100,000 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
Male-to-female ratio Approximately 3:1 2019, GBD 2019; also male predominance across regions in 2022 GLOBOCAN (ilic2024globalburdenof pages 4-6, qi2024globalesophagealcancer pages 1-2)
5-year survival rate <20% 2021, GBD 2021 / recent global reviews (zhang2025burdenofesophageal pages 1-2, sheikh2023currentstatusand pages 15-16)
China’s share of global cases 43.8% 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
East Asia share of global cases 53.2% 2019, GBD 2019 (ilic2024globalburdenof pages 4-6, ilic2024globalburdenof pages 2-4)
Highest-risk regions East Africa and East Asia: ASIR 7.60 per 100,000 2022, GLOBOCAN (qi2024globalesophagealcancer pages 1-2)
DALYs 12,999,264 2021, GBD 2021 (zhang2025burdenofesophageal pages 1-2)
Projected cases by 2050 +80.5% vs 2022 2050 projection from GLOBOCAN-based analysis (qi2024globalesophagealcancer pages 1-2)
Smoking attribution 50.1% of DALYs in males 2019, GBD 2019 (ilic2024globalburdenof pages 6-10)
Alcohol attribution 29.6% of DALYs in males 2019, GBD 2019 (ilic2024globalburdenof pages 6-10)
High BMI attribution 18.8% of DALYs in males 2019, GBD 2019 (ilic2024globalburdenof pages 6-10)

Table: This table summarizes the recent global epidemiological burden of esophageal cancer using GLOBOCAN 2022 and GBD 2019/2021 data. It highlights incidence, mortality, geographic concentration, sex disparity, survival, future projections, and major attributable risk factors.

In 2019, there were 534,563 new cases globally (388,827 males, 145,736 females), with an age-standardized incidence rate of 6.5 per 100,000 (ilic2024globalburdenof pages 4-6). East Asia accounted for 53.2% of cases, with China representing 97.6% of those. The highest incidence rates (~17 per 100,000) occurred in Mongolia and Malawi (ilic2024globalburdenof pages 4-6). Age-standardized rates have been declining since 1990 (24.87% decrease in incidence by 2021), though absolute numbers continue to rise due to population growth and aging (zhang2025burdenofesophageal pages 1-2). By 2050, new cases are projected to increase by 80.5% and deaths by 85.4% compared to 2022 levels (qi2024globalesophagealcancer pages 1-2).

Genetic Inheritance

EC is a complex, multifactorial disease with polygenic susceptibility. It does not follow a Mendelian inheritance pattern except in rare syndromes: - Tylosis (Howel-Evans syndrome): Autosomal dominant; associated with RHBDF2 mutations; strongly predisposes to ESCC. - GWAS have identified susceptibility loci including ADH1B, ALDH2, PLCE1, SLC39A6, and others (zhang2026esophagealcancerfrom pages 2-3, OpenTargets Search: esophageal carcinoma).

Population Demographics

  • Sex ratio: Males have approximately 3-fold higher incidence and mortality than females across all regions (zhang2026esophagealcancerfrom pages 2-3, ilic2024globalburdenof pages 4-6).
  • Geographic distribution: ESCC is most prevalent in the "Asian esophageal cancer belt" (extending from northern Iran through Central Asia to northern China), and in East and Southern Africa. EAC is most common in Western Europe, North America, and Oceania (ilic2024globalburdenof pages 13-15, qi2024globalesophagealcancer pages 1-2).
  • Ethnic variation: ESCC predominates in East Asian and Sub-Saharan African populations; EAC is more common in Caucasian populations (li2023molecularbiologyand pages 1-2).

10. Diagnostics

Clinical Tests

  • Upper gastrointestinal endoscopy with biopsy is the gold standard for diagnosis (sheikh2023currentstatusand pages 15-16). MAXO:0000130 (endoscopy).
  • Endoscopic ultrasound (EUS): Standard technique for locoregional staging (sheikh2023currentstatusand pages 15-16).
  • Cross-sectional imaging: CT, MRI, PET/CT for distant staging (rai2023biomarkersforearly pages 6-8).
  • Advanced endoscopy: Chromoendoscopy, virtual chromoendoscopy, confocal laser endomicroscopy, volumetric laser endomicroscopy (rai2023biomarkersforearly pages 6-8).

Biomarkers

  • HER2 (ERBB2): Positive in 15–29% of EAC; FDA companion diagnostic for trastuzumab (rai2023biomarkersforearly pages 8-9).
  • PD-L1: FDA-approved companion diagnostic for immunotherapy; present in ≤27% of EAC tumors (rai2023biomarkersforearly pages 8-9).
  • Microsatellite instability (MSI-H)/dMMR: Enhanced sensitivity to immune checkpoint inhibitors (fick2024immunotherapyforresectable pages 7-7).
  • Tumor mutational burden (TMB): FDA-approved companion diagnostic for pembrolizumab (rai2023biomarkersforearly pages 1-3).
  • Circulating tumor DNA (ctDNA): Emerging prognostic biomarker detected via NGS (rai2023biomarkersforearly pages 6-8, fick2024immunotherapyforresectable pages 9-10).
  • DNA methylation markers: Non-invasive approaches including blood cfDNA methylation and esophageal exfoliated cell-based DNA methylation analysis show promise for early detection (rai2023biomarkersforearly pages 6-8).
  • 5-hydroxymethylcytosine (5hmC) signatures: Combined with low-pass WGS, achieves AUC of 0.934 for ESCC detection with 82.4% sensitivity and 88.2% specificity.

Screening

  • Endoscopy-based screening in high-incidence regions (China, Japan) meets cost-effectiveness criteria and has demonstrated 43% reduction in SCC incidence and 45% reduction in mortality (liu2023epidemiologyofesophageal pages 6-7).
  • Cytosponge™: Non-endoscopic swallowable device for Barrett's esophagus detection, combined with TFF3 biomarker immunohistochemistry (sheikh2023currentstatusand pages 15-16).
  • Liquid biopsy: Blood, urine, and saliva-based non-invasive screening approaches under development (rai2023biomarkersforearly pages 1-3).

11. Outcome/Prognosis

Survival and Mortality

  • 5-year survival rate: Less than 20% overall; as low as 15% in some populations (zhang2025burdenofesophageal pages 1-2, sheikh2023currentstatusand pages 15-16).
  • Early detection survival: When detected early, endoscopic removal achieves 5-year survival rates up to 95% (zhang2026esophagealcancerfrom pages 2-3).
  • Advanced disease: Metastatic disease treated with first-line chemotherapy achieves median survival of less than 1 year (jazieh2024advancesinimmunotherapy pages 1-3).
  • Mortality: 445,391 deaths globally in 2022 with ASMR of 4.30 per 100,000; mortality-to-incidence ratio is high (qi2024globalesophagealcancer pages 1-2).

Prognostic Factors

  • Disease stage at diagnosis (most important)
  • Histological subtype (ESCC vs. EAC)
  • PD-L1 expression and MSI-H/dMMR status for immunotherapy response prediction
  • Serum IL-6 levels: Higher levels predict worse prognosis and increased immune-related adverse events with immunotherapy
  • CD39+ tumor-infiltrating T cells correlate with favorable prognosis (chen2025singlecellatlasof pages 2-3)
  • CXCL13+CD8+ exhausted T cells predict improved response to neoadjuvant immunochemotherapy (ji2024singlecellprofilingof pages 1-2)

12. Treatment

Pharmacotherapy

Chemotherapy

  • First-line regimens: Fluorinated pyrimidine plus platinum agent (cisplatin or oxaliplatin) ± taxane (jazieh2024advancesinimmunotherapy pages 1-3).
  • Neoadjuvant regimens: CROSS regimen (carboplatin/paclitaxel + radiotherapy); FLOT regimen (5-FU/leucovorin/oxaliplatin/docetaxel) for perioperative EAC treatment (li2023molecularbiologyand pages 1-2, fick2024immunotherapyforresectable pages 7-7).

Immunotherapy

  • Pembrolizumab (anti-PD-1): FDA-approved (March 2021, KEYNOTE-590 trial) for first-line advanced EC combined with chemotherapy (rai2023biomarkersforearly pages 8-9, jazieh2024advancesinimmunotherapy pages 1-3). MAXO:0001287 (immune checkpoint inhibitor therapy).
  • Nivolumab (anti-PD-1): FDA-approved for adjuvant use after neoadjuvant chemoradiotherapy and surgery in patients with residual disease (CheckMate 577); improved median DFS 22.4 vs. 11.0 months, particularly in ESCC (29.7 vs. 11.0 months) (fick2024immunotherapyforresectable pages 7-7, zhang2026esophagealcancerfrom pages 21-21).
  • Anti-PD-1 plus platinum-based chemotherapy has replaced chemotherapy alone as the standard first-line treatment for most advanced EC patients (zhang2026esophagealcancerfrom pages 21-21).
  • Pathologic complete response rates with ICI plus chemoradiotherapy reach up to 60% in early-phase trials, with highest rates in ESCC and dMMR tumors (fick2024immunotherapyforresectable pages 1-2).

Targeted Therapy

  • Trastuzumab: HER2-directed therapy for HER2-positive EAC (15–29% of cases); FDA companion diagnostic required (rai2023biomarkersforearly pages 8-9). MAXO:0001298 (HER2 targeted therapy).
  • CLDN18.2-targeting therapies: Zolbetuximab (anti-CLDN18.2 antibody) and AZD6422 (armored CAR-T targeting CLDN18.2) are in clinical development for CLDN18.2+ esophagogastric cancers.
  • EGFR inhibitors: Cetuximab studied but has not significantly improved OS in meta-analyses despite EGFR overexpression in 20–50% of EAC tumors (rai2023biomarkersforearly pages 8-9).

Surgical Interventions

  • Esophagectomy: Radical resection remains a cornerstone for resectable disease, typically after neoadjuvant therapy. R0 resection rates with neoadjuvant immunotherapy approaches are high (up to 98%) (fick2024immunotherapyforresectable pages 4-5). MAXO:0000004 (surgical procedure).
  • Endoscopic treatments: EMR (endoscopic mucosal resection) and ESD (endoscopic submucosal dissection) for early-stage disease without lymph node involvement (sheikh2023currentstatusand pages 15-16). MAXO:0000130 (endoscopy).

Experimental Treatments

  • Neoadjuvant chemo-immunotherapy: Phase III trials investigating perioperative ICI combinations ongoing (fick2024immunotherapyforresectable pages 1-2, fick2024immunotherapyforresectable pages 5-7).
  • CAR-T therapy: Mesothelin-targeted (M28z1XXPD1DNR) CAR-T for peritoneal carcinomatosis (NCT06623396); CLDN18.2-targeting CAR-T (AZD6422) in clinical development.
  • Personalized neoantigen vaccines: NCT05307835 investigating tumor-specific antigen vaccination (fick2024immunotherapyforresectable pages 9-10).
  • Anti-TIGIT combinations: Multiple clinical trials combining TIGIT blockade with anti-PD-1 for esophagogastric cancers.

Treatment Outcomes

  • Neoadjuvant chemoradiotherapy with immunotherapy: pooled pCR rates of 31.4%, MPR rates of 48.9% (fick2024immunotherapyforresectable pages 5-7).
  • Immunotherapy addition to chemoradiotherapy associated with higher pCR (29% vs. 21%), improved nodal downstaging (50% vs. 40%), and longer median OS (69.1 vs. 56.3 months) (fick2024immunotherapyforresectable pages 5-7).
  • ICI response rates remain ≤30% overall, with immune-related adverse events in 17% of cases (Grade 3+) (rai2023biomarkersforearly pages 8-9).

13. Prevention

Primary Prevention

  • Tobacco cessation and alcohol reduction are the most impactful strategies, as smoking and alcohol account for ~90% of ESCC in Western countries (jiang2023globaltrendsin pages 12-13).
  • Dietary modification: Increased intake of fresh fruits and vegetables; avoidance of moldy foods and nitrosamine-containing foods (qi2024globalesophagealcancer pages 1-2).
  • Weight management: Reducing obesity to lower EAC risk (high BMI accounts for 18.8–19.3% of DALYs) (ilic2024globalburdenof pages 6-10).
  • GERD management: Proton pump inhibitors and lifestyle modifications to prevent Barrett's esophagus progression (sheikh2023currentstatusand pages 15-16).

Secondary Prevention (Screening and Early Detection)

  • Endoscopic screening in high-incidence populations has demonstrated significant mortality reduction (45% in community-based Chinese studies) (liu2023epidemiologyofesophageal pages 6-7).
  • Cytosponge™ combined with biomarker assays for non-endoscopic Barrett's screening (sheikh2023currentstatusand pages 15-16).
  • Risk stratification using genetic markers, clinical factors, and molecular biomarkers for targeted screening.
  • Endoscopy-based early diagnosis in China and Japan has advanced endoscopic methods as definitive treatments with remarkable efficacy (zhang2026esophagealcancerfrom pages 1-2).

Chemoprevention

  • Aspirin and proton pump inhibitors have shown promising results in chemoprevention of EAC from Barrett's esophagus (sheikh2023currentstatusand pages 15-16).

14. Other Species / Natural Disease

Esophageal cancer naturally occurs in various animal species, though it is less extensively documented than in humans. The condition has been observed in: - Dogs (Canis lupus familiaris): Esophageal carcinoma, though rare, has been documented; spirocercosis (Spirocerca lupi) infection is a known risk factor for esophageal sarcoma in dogs. - Cattle (Bos taurus): Esophageal papillomas and carcinomas associated with bovine papillomavirus and bracken fern consumption.

15. Model Organisms

Cell Lines

Extensively used ESCC cell lines include the KYSE series (KYSE-30, KYSE-150, KYSE-180, KYSE-450, KYSE-510), TE-1, ECA-109, and KYSE-770, with the normal epithelial line Het-1a as control. Whole exome and RNA sequencing have characterized their genomic landscape, revealing TMB ranging from 48.7 to 70.4 mut/MB, with mutations in Hippo, Notch, PI3K, RTK-Ras, and Wnt pathways across all cancer cell lines (zhang2025thegenomiclandscape pages 4-7). Human esophageal squamous cell lines KYSE140, KYSE150, KYSE450, KYSE510, KYSE30, KYSE70, and KYSE410 are widely used (liu2023spatialtranscriptomicsanalysis pages 16-17).

Mouse Models

  • 4-NQO (4-nitroquinoline-1-oxide)-induced spontaneous ESCC mouse model: Chemical carcinogen administered in drinking water to induce ESCC, recapitulating the multistep carcinogenesis process. This model has been used to validate therapeutic targets including CCL18 blockade.
  • Xenograft models: CB17 SCID immunodeficient mice used for subcutaneous and orthotopic tumor growth studies (liu2023spatialtranscriptomicsanalysis pages 16-17).
  • Patient-derived xenograft (PDX) models: Preserve patient tumor features and are used for drug efficacy testing and personalized medicine approaches.

Organoid Models

Patient-derived organoids (PDOs) maintain in Matrigel culture for 10–14 days and can be genetically modified via lentivirus-mediated transduction. PDOs have been used for coculture experiments to test T cell cytotoxicity (liu2023spatialtranscriptomicsanalysis pages 16-17, chen2025singlecellatlasof pages 3-5). Organoid models are increasingly used in the research and development of antitumor drugs and personalized medicine.

Model Limitations

Cell line-derived xenograft models lack patient tumor heterogeneity and immune microenvironment characteristics. PDX and organoid models better preserve patient features but remain limited in recapitulating the full immune microenvironment, particularly the adaptive immune response.

Summary

Esophageal carcinoma remains one of the most lethal and challenging cancers globally, with high mortality rates and poor overall prognosis. The two major subtypes, ESCC and EAC, exhibit distinct epidemiological patterns, risk factor profiles, molecular landscapes, and geographic distributions. Recent advances in single-cell and spatial transcriptomics have revealed unprecedented detail about the tumor microenvironment, identifying cell-type-specific mechanisms of immune evasion and treatment resistance. The integration of immune checkpoint inhibitors, particularly anti-PD-1 antibodies, into treatment paradigms has significantly improved outcomes for both subtypes, with adjuvant nivolumab and first-line pembrolizumab plus chemotherapy now established as standard-of-care options. Emerging therapeutic modalities including CAR-T cell therapy, personalized neoantigen vaccines, and novel checkpoint combinations hold promise for further improvements. Primary prevention through tobacco cessation, alcohol reduction, and dietary modification remains the most effective strategy for reducing the global burden of this disease, while advances in non-invasive screening technologies and liquid biopsy approaches may enable earlier detection and improved survival outcomes in the future.

References

  1. (qi2024globalesophagealcancer pages 1-2): Ling Qi, Mengfei Sun, Weixin Liu, Xuefeng Zhang, Yongjun Yu, Ziqiang Tian, Zhiyu Ni, Rongshou Zheng, and Yong Li. Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on globocan data. Chinese Medical Journal, 137:3108-3116, Dec 2024. URL: https://doi.org/10.1097/cm9.0000000000003420, doi:10.1097/cm9.0000000000003420. This article has 75 citations and is from a peer-reviewed journal.

  2. (zhang2026esophagealcancerfrom pages 1-2): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  3. (sheikh2023currentstatusand pages 15-16): Mahdi Sheikh, Gholamreza Roshandel, Valerie McCormack, and Reza Malekzadeh. Current status and future prospects for esophageal cancer. Cancers, 15:765, Jan 2023. URL: https://doi.org/10.3390/cancers15030765, doi:10.3390/cancers15030765. This article has 294 citations.

  4. (OpenTargets Search: esophageal carcinoma): Open Targets Query (esophageal carcinoma, 40 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  5. (li2023molecularbiologyand pages 1-2): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

  6. (zhang2026esophagealcancerfrom pages 6-7): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  7. (zhang2026esophagealcancerfrom pages 9-10): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  8. (zhang2026esophagealcancerfrom pages 2-3): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  9. (li2023molecularbiologyand pages 6-8): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

  10. (liu2023epidemiologyofesophageal pages 8-9): Chun‐Quan Liu, Yun‐Lei Ma, Qi Qin, Pei‐Hao Wang, Yi Luo, Peng‐Fei Xu, and Yong Cui. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thoracic Cancer, 14:3-11, Dec 2023. URL: https://doi.org/10.1111/1759-7714.14745, doi:10.1111/1759-7714.14745. This article has 457 citations.

  11. (ilic2024globalburdenof pages 6-10): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

  12. (ilic2024globalburdenof pages 4-6): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

  13. (fick2024immunotherapyforresectable pages 9-10): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

  14. (rai2023biomarkersforearly pages 8-9): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

  15. (zhang2025thegenomiclandscape pages 4-7): Chao Zhang, Chenghao Li, Jian Zhong Su, Kuaile Zhao, Longlong Shao, and Jiaying Deng. The genomic landscape of esophageal squamous cell carcinoma cell lines. Cancer Cell International, May 2025. URL: https://doi.org/10.1186/s12935-025-03686-1, doi:10.1186/s12935-025-03686-1. This article has 7 citations and is from a peer-reviewed journal.

  16. (zhang2026esophagealcancerfrom pages 8-9): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  17. (li2023molecularbiologyand pages 16-17): Shulin Li, Sanne Johanna Maria Hoefnagel, and Kausilia Krishnawatie Krishnadath. Molecular biology and clinical management of esophageal adenocarcinoma. Cancers, 15:5410, Nov 2023. URL: https://doi.org/10.3390/cancers15225410, doi:10.3390/cancers15225410. This article has 24 citations.

  18. (zhang2026esophagealcancerfrom pages 30-31): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  19. (zhang2026esophagealcancerfrom pages 21-21): Shaosen Zhang, Yanrong Shen, Lingxuan Zhu, Yancheng Lai, Liang Zhu, Xinyi Xiao, Jiacheng Li, Wen Tan, Dongxin Lin, and Chen Wu. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduction and Targeted Therapy, Apr 2026. URL: https://doi.org/10.1038/s41392-026-02614-7, doi:10.1038/s41392-026-02614-7. This article has 1 citations and is from a peer-reviewed journal.

  20. (jazieh2024advancesinimmunotherapy pages 1-3): Khalid Jazieh, Harry H Yoon, and Mojun Zhu. Advances in immunotherapy in esophagogastric cancer. Jun 2024. URL: https://doi.org/10.1016/j.hoc.2024.02.002, doi:10.1016/j.hoc.2024.02.002. This article has 1 citations.

  21. (chen2025singlecellatlasof pages 5-6): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

  22. (maslenkina2023signalingpathwaysin pages 14-16): Ksenia Maslenkina, Liudmila Mikhaleva, Maxim Naumenko, Rositsa Vandysheva, Michail Gushchin, Dmitri Atiakshin, Igor Buchwalow, and Markus Tiemann. Signaling pathways in the pathogenesis of barrett’s esophagus and esophageal adenocarcinoma. International Journal of Molecular Sciences, May 2023. URL: https://doi.org/10.3390/ijms24119304, doi:10.3390/ijms24119304. This article has 26 citations.

  23. (jiang2023globaltrendsin pages 12-13): Yu Jiang, Yuechun Lin, Yaokai Wen, Wenhai Fu, Rui Wang, Jiaxi He, Jianrong Zhang, Zhufeng Wang, Fan Ge, Zhenyu Huo, Runchen Wang, Haoxin Peng, Xiangrong Wu, Jianxing He, and Shuben Li. Global trends in the burden of esophageal cancer, 1990−2019: results from the global burden of disease study 2019. Journal of Thoracic Disease, 15:348-364, Feb 2023. URL: https://doi.org/10.21037/jtd-22-856, doi:10.21037/jtd-22-856. This article has 43 citations and is from a peer-reviewed journal.

  24. (rai2023biomarkersforearly pages 6-8): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

  25. (fick2024immunotherapyforresectable pages 4-5): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

  26. (ji2024singlecellprofilingof pages 1-2): Gang Ji, Qi Yang, Song Wang, Xiaolong Yan, Qiuxiang Ou, Li Gong, Jinbo Zhao, Yongan Zhou, Feng Tian, Jie Lei, Xiaorong Mu, Jian Wang, Tao Wang, Xiaoping Wang, Jianyong Sun, Jipeng Zhang, Chenghui Jia, Tao Jiang, Ming-gao Zhao, and Qiang Lu. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Medicine, Apr 2024. URL: https://doi.org/10.1186/s13073-024-01320-9, doi:10.1186/s13073-024-01320-9. This article has 52 citations and is from a highest quality peer-reviewed journal.

  27. (chen2025singlecellatlasof pages 2-3): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

  28. (guo2025singlecellrnasequencing pages 3-3): Wei Guo, Bolun Zhou, Lizhou Dou, Lei Guo, Yong Li, Jianjun Qin, Zhen Wang, Qilin Huai, Xuemin Xue, Yin Li, Jianming Ying, Qi Xue, Shugeng Gao, and Jie He. Single-cell rna sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases. Experimental & Molecular Medicine, 57:59-71, Jan 2025. URL: https://doi.org/10.1038/s12276-024-01369-x, doi:10.1038/s12276-024-01369-x. This article has 15 citations and is from a peer-reviewed journal.

  29. (yin2025singlecelltranscriptomicanalysis pages 1-2): Xiaolei Yin, Xiaopeng Li, Lili Mi, Jiaojiao Hou, and Fei Yin. Single-cell transcriptomic analysis reveals epithelial and microenvironmental heterogeneity in small cell carcinoma of the esophagus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1672587, doi:10.3389/fimmu.2025.1672587. This article has 1 citations and is from a peer-reviewed journal.

  30. (yin2025singlecelltranscriptomicanalysis pages 14-15): Xiaolei Yin, Xiaopeng Li, Lili Mi, Jiaojiao Hou, and Fei Yin. Single-cell transcriptomic analysis reveals epithelial and microenvironmental heterogeneity in small cell carcinoma of the esophagus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1672587, doi:10.3389/fimmu.2025.1672587. This article has 1 citations and is from a peer-reviewed journal.

  31. (zhang2025burdenofesophageal pages 1-2): Chengcheng Zhang, Linzhi Chen, Yuqi Xiu, Hongling Zhang, Yuejuan Zhang, and Wenjuan Ying. Burden of esophageal cancer in global, regional and national regions from 1990 to 2021 and its projection until 2050: results from the gbd study 2021. Frontiers in Oncology, Jan 2025. URL: https://doi.org/10.3389/fonc.2024.1518567, doi:10.3389/fonc.2024.1518567. This article has 17 citations.

  32. (ilic2024globalburdenof pages 2-4): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

  33. (ilic2024globalburdenof pages 13-15): Irena Ilic, Ivana Zivanovic Macuzic, Ana Ravic-Nikolic, Milena Ilic, and Vesna Milicic. Global burden of esophageal cancer and its risk factors: a systematic analysis of the global burden of disease study 2019. Life, 15:24, Dec 2024. URL: https://doi.org/10.3390/life15010024, doi:10.3390/life15010024. This article has 15 citations.

  34. (fick2024immunotherapyforresectable pages 7-7): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

  35. (rai2023biomarkersforearly pages 1-3): Vikrant Rai, Joe Abdo, and Devendra K. Agrawal. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences, 24:3316, Feb 2023. URL: https://doi.org/10.3390/ijms24043316, doi:10.3390/ijms24043316. This article has 73 citations.

  36. (liu2023epidemiologyofesophageal pages 6-7): Chun‐Quan Liu, Yun‐Lei Ma, Qi Qin, Pei‐Hao Wang, Yi Luo, Peng‐Fei Xu, and Yong Cui. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thoracic Cancer, 14:3-11, Dec 2023. URL: https://doi.org/10.1111/1759-7714.14745, doi:10.1111/1759-7714.14745. This article has 457 citations.

  37. (fick2024immunotherapyforresectable pages 1-2): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

  38. (fick2024immunotherapyforresectable pages 5-7): Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, Daniela Molena, Samuel L. Cytryn, Yelena Y. Janjigian, Abraham J. Wu, Stephanie G. Worrell, Wayne L. Hofstetter, David R. Jones, and Katherine D. Gray. Immunotherapy for resectable locally advanced esophageal carcinoma. The Annals of Thoracic Surgery, 118:130-140, Jul 2024. URL: https://doi.org/10.1016/j.athoracsur.2024.02.021, doi:10.1016/j.athoracsur.2024.02.021. This article has 18 citations.

  39. (liu2023spatialtranscriptomicsanalysis pages 16-17): Xuejiao Liu, Simin Zhao, Keke Wang, Liting Zhou, Ming Jiang, Yunfeng Gao, Ran Yang, Shiwen Yan, Wen Zhang, Bingbing Lu, Feifei Liu, Ran Zhao, Wenting Liu, Zihan Zhang, Kangdong Liu, Xiang Li, and Zigang Dong. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-40343-5, doi:10.1038/s41467-023-40343-5. This article has 62 citations and is from a highest quality peer-reviewed journal.

  40. (chen2025singlecellatlasof pages 3-5): Xiankai Chen, Yahui Zhao, Yuhao Wang, Xiliang Wang, Yuhao Liu, Zhihua Liu, and Yin Li. Single-cell atlas of the esophageal squamous cell carcinoma immune ecosystem to predict immunotherapy response. Signal Transduction and Targeted Therapy, Oct 2025. URL: https://doi.org/10.1038/s41392-025-02446-x, doi:10.1038/s41392-025-02446-x. This article has 8 citations and is from a peer-reviewed journal.

Artifacts